Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718601 | 0.81 | TP53 (0.61) | GAAMAPTRAB9AALDH1A1ALOX15 | |
| SCHEMBL5693381 | 0.80 | PRMT6 (0.47) | GAAMAPTRAB9AALDH1A1ALOX15 | |
| SCHEMBL6297638 | 0.79 | FFAR1 (0.56) | GAAMAPTRAB9AALDH1A1ALOX15 | |
| SCHEMBL5682277 | 0.77 | GAA (0.54) | GAAMAPTRAB9AALDH1A1ALOX15 | |
| SCHEMBL5362798 | 0.77 | GAA (0.54) | GAAMAPTRAB9AALDH1A1ALOX15 | |
| SCHEMBL5682278 | 0.74 | ALDH1A1 (0.52) | GAAMAPTRAB9AALDH1A1ALOX15 | |
| SCHEMBL5350063 | 0.74 | CA1 (0.56) | GAAMAPTRAB9AALDH1A1ALOX15 | |
| SCHEMBL14071630 | 0.74 | MAOA (0.42) | GAAMAPTRAB9AALDH1A1ALOX15 | |
| SCHEMBL14869697 | 0.74 | PRMT6 (0.52) | GAAMAPTRAB9AALDH1A1ALOX15 | |
| SCHEMBL5713825 | 0.73 | GAA (0.49) | GAAMAPTRAB9AALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887281-B2 | N-heteroarylmethyl-p-phenylenediamine derivatives as well as oxidation dyeing agents containing these compounds | WELLA AKTIENGESELLSCHAFT (DE) | 2005-05-03 | — | — | US | claimed |
| US-20050015898-A1 | N-heteroarylmethyl-p-phenylenediamine derivatives as well as oxidation dyeing agents containing these compounds | HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) | 2005-01-27 | — | — | US | claimed |
| US-6953791-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6951850-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6924280-B2 | Dipeptide derivatives | PFIZER INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-6887281-B2 | N-heteroarylmethyl-p-phenylenediamine derivatives as well as oxidation dyeing agents containing these compounds | WELLA AKTIENGESELLSCHAFT (DE) | 2005-05-03 | — | — | US | disclosed |
| US-6849097-B2 | N-heteroarylmethyl-p-phnylendiamine derivatives and compounds containing oxidationcoloring agents | WELLA AKTIENGESELLSCHAFT (DE) | 2005-02-01 | — | — | US | disclosed |
| US-20050015898-A1 | N-heteroarylmethyl-p-phenylenediamine derivatives as well as oxidation dyeing agents containing these compounds | HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) | 2005-01-27 | — | — | US | disclosed |
| US-RE38524-E1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2004-06-01 | — | — | US | disclosed |
| EP-1313724-B1 | N-HETEROARYLMETHYL-P-PHENYLENDIAMINE DERIVATIVES AND COMPOUNDS CONTAINING OXIDATION COLOURING AGENTS | WELLA AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | CARPINO PHILIP ALBERT (US) | 2004-01-15 | — | — | US | disclosed |
| EP-1313724-A1 | N-HETEROARYLMETHYL-P-PHENYLENDIAMINE DERIVATIVES AND COMPOUNDS CONTAINING OXIDATION COLOURING AGENTS | Wella Aktiengesellschaft (DE) | 2003-05-28 | — | — | EP | disclosed |
| US-20030070240-A1 | N-heteroarylmethyl-p-phnylendiamine derivatives and compounds containing oxidationcoloring agents | HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) | 2003-04-17 | — | — | US | disclosed |
| US-6525047-B2 | Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair | PFIZER INC. | 2003-02-25 | — | — | US | disclosed |
| US-6432945-B1 | Dipeptide derivatives | PFIZER INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020042415-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2002018365-A1 | N-HETEROARYLMETHYL-P-PHENYLENDIAMINE DERIVATIVES AND COMPOUNDS CONTAINING OXIDATION COLOURING AGENTS | WELLA AKTIENGESELLSCHAFT (DE) | 2002-03-07 | — | — | WO | disclosed |
| US-20010041703-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2001-11-15 | — | — | US | disclosed |
| US-6251902-B1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | GHSR, GHRHR, GIPR | GAA 1947/4885MAPT 4844/4885RAB9A 4040/4885 |
| US-20030070240-A1 | N-heteroarylmethyl-p-phnylendiamine derivatives and compounds containing oxidationcoloring agents | PNMT, PAH, CYP2E1 | GAA 2861/4885MAPT 2997/4885RAB9A 3784/4885 |
| US-20020042415-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GAA 3583/4885MAPT 4862/4885RAB9A 4472/4885 |
| US-20010041703-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GAA 3543/4885MAPT 4845/4885RAB9A 4339/4885 |
| US-20050015898-A1 | N-heteroarylmethyl-p-phenylenediamine derivatives as well as oxidation dyeing agents containing these compounds | TYR, PNMT, DDT | GAA 2903/4885MAPT 3455/4885RAB9A 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.